Bio Box Australia • Ep 3

A Fundamental Shift in Clinical Trial Design to Save Time & Money


VIDEO: Bio Box Australia • Ep 3

Traditional clinical trial designs represent established approaches to bring new therapies to patients. Current approaches used to pinpoint suitable doses rely on dosing cohorts which often result in population-based doses, which while suitable for translation, can result in sub-optimal dosing and patient response on a larger scale. To address this challenge, artificial intelligence has been explored to enable patient-specific dosing that uses a patient’s own data to manage only their own care. This scalable approach, which is mechanism-independent and disease indication agnostic has been studied in pilot N-of-1 trials for oncology, infectious diseases, and transplant, and may lead to improved patient response rates and outcomes.

Prof. Dean Ho, Provost’s Chair Professor, Director of The N.1 Institute for Health (N.1), Director of the Institute for Digital Medicine (WisDM), and Head of the Department of Biomedical Engineering at the National University of Singapore